The Latest Breaking News from Vertex Pharmaceuticals

Vertex Pharmaceuticals has outperformed the broader market in 2024 but Wall Street analysts remain cautiously bullish about the stock's potential.

The best mutual funds spurned Nvidia and Microsoft last month. They got up and went to GoDaddy and these builders.

A Relative Strength Rating upgrade for Vertex stock shows improving technical performance. Will it continue?

After a solid first-quarter earnings report, Vertex Pharmaceuticals (VRTX) comfortably topped analysts’ earnings and revenue estimates in the first quarter. But should investors consider adding the stock to their portfolio now? Let’s look at its financial metrics to gauge its prospects….

Vertex stock advanced Tuesday as analysts debated the company's pain drug with one saying it could eventually generate $11.4 billion in sales.

The Dow fell after initially rising on the PPI inflation report on the stock market today. Analysts hiked Microsoft and Nvidia price targets.

Vertex Pharmaceuticals will pay $4.9 billion to acquire Alpine Immune Sciences. Alpine stock rocketed almost 21% on rumors of the deal.

S&P 500 stocks Lennar, Vertex Pharmaceuticals and Royal Caribbean lead this list of five stocks trading around buy points.

Vertex is the IBD Stock Of The Day. VRTX stock bounced off its 50-day line as investors watch for the first sales of its gene-editing drug.

Vertex Pharmaceuticals just released data from its experimental drug to relieve pain, with no risk of addiction and very few side effects. This opioid alternative could give Vertex - already a powerhouse in the cystic fibrosis segment - another blockbuster drug to add to its portfolio.

The Dow Jones hit a record high while the S&P 500, Nasdaq and Russell 2000 set 2023 highs as the Fed signaled multiple rate cuts next year.